



Introduction: The validation process is essential in accredited clinical laboratories. Aim of this study was to validate fi ve kinds of serum vacuum 
tubes for routine clinical chemistry laboratory testing.
Materials and methods: Blood specimens from 100 volunteers in fi ve diff erent serum vacuum tubes (Tube I: VACUETTE®, Tube II: LABOR IMPORT®, 
Tube III: S-Monovette®, Tube IV: SST® and Tube V: SST II®) were collected by a single, expert phlebotomist. The routine clinical chemistry tests were 
analyzed on cobas® 6000 <c501> module. The signifi cance of the diff erences between samples was assessed by paired Student’s t-test after che-
cking for normality. The level of statistical signifi cance was set at P < 0.005. Finally, the biases from Tube I, Tube II, Tube III, Tube IV and Tube V were 
compared with the current desirable quality specifi cations for bias (B), derived from biological variation.
Results and conclusions: Basically, our validation will permit the laboratory or hospital managers to select the brand’s vacuum tubes validated 
according him/her technical or economical reasons, in order to perform the following laboratory tests: glucose, total cholesterol, high density lipo-
protein-cholesterol, triglycerides, total protein, albumin, blood urea nitrogen, uric acid, alkaline phosphatise, aspartate aminotransferase, gamma-
glutamyltransferase, lactate dehydrogenase, creatine kinase, total bilirubin, direct bilirubin, calcium, iron, sodium and potassium. On the contrary 
special attention will be required if the laboratory already performs creatinine, amylase, phosphate and magnesium determinations and the quality 
laboratory manager intend to change the serum tubes. We suggest that laboratory management should both standardize the procedures and fre-
quently evaluate the quality of in vitro diagnostic devices. 
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Laboratory testing is an integral part of the deci-
sion-making process, and results of laboratory 
testing often strongly infl uence medical diagnoses 
and therapies. There is a long history of quality re-
quirements in laboratory medicine, which have 
mainly concerned the analytic phase of this proc-
ess (1). Owing to the substantial advances in tech-
nology, laboratory automation and analytic quali-
ty, there is increasing evidence that further quality 
improvements should be targeted to extra-analyt-
ic phases of laboratory testing (2-6). Clinical labo-
ratories routinely use commercial diagnostic prod-
ucts during the testing process. Diagnostic prod-
ucts can be divided into two major categories: in 
vitro diagnostic (IVD) devices, such as laboratory 
instruments, reagents, assays and blood collection 
tubes, and medical devices, such as specimen col-
lection devices (needles and sets) (7). Necessary 
improvements and potential sources of noncon-
formities, either technical or concerning the quali-
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ty management system, shall be identifi ed and all 
laboratory process shall be validated (8). Some IVD 
devices (e.g. blood collection vacuum tubes) are 
not validated before the quality laboratory man-
agers decide to start using or to change the brand. 
The aim of this study was to validate fi ve kinds of 




A group of 100 adult ambulatory patients of both 
genders, volunteers for this study, from Dante Paz-
zanese Cardiology Insitute, São Paulo city, Brazil, 
were evaluated between 1st September and 1st Oc-
tober 2011. This study was submitted to the Inter-
nal Review Board and approved by the local Hu-
man Research Ethics Committee. All volunteers 
signed an informed consent.
Collection of diagnostic blood specimens
The collection of all diagnostic blood specimens 
was performed from 8.00 to 9.00 AM during one 
week by a single, expert phlebotomist, according 
to the recommendations of the Clinical Laboratory 
Standard Institute (CLSI) (9). All volunteers, after 
12-hours fasting, were maintained seated for 15 
minutes prior to phlebotomy in order to eliminate 
possible interferences of blood distribution due to 
the posture (10). After this time interval, a vein was 
located on forearm by a subcutaneous tissue tran-
silluminator device (Venoscópio IV plus, Duan do 
Brasil, Sao Paulo, Brazil) to prevent interference 
from venous stasis (11-13), and 23.9 mL of blood 
was collected by venipuncture with a 20 G straight 
needle (Terumo Europe NV, Leuven, Belgium) di-
rectly into fi ve serum vacuum tubes with clot acti-
vator and gel separator of diff erent brands, as fol-
lows:
Tube I: VACUETTE® 4.0 mL (lot C080818, Greiner • 
Bio-one GmbH, Kremsmünster, Austria);
Tube II: LABOR IMPORT® 6.0 mL (lot C38005-6, • 
Guangzhou Improve Medical Instruments Co. 
Ltda, Zhejiang, China);
Tube III: S-Monovette® 4.9 mL (lot 8092506, • 
Sarstedt, Nümbrecht, Germany);
Tube IV: SST® 4.0 mL (lot 8308434, Becton, Dickin-• 
son and Company Franklin Lakes, NJ, USA); and
Tube V: SST II Advance® 5.0 mL (lot 8225174, • 
Becton, Dickinson and Company Franklin Lakes, 
NJ, USA).
To eliminate any potential interference due to ei-
ther the contact phase or the tissue factor, ~2 mL 
of blood were preliminarily collected in a discard 
tube without additive (Vacuette® lot A101004D, 
Greiner Bio-One GmbH, Kremsmünster, Austria). 
The exact composition of the gel separator and 
amount of clot activator inside the vacuum tubes 
was not communicated by manufactures, as pat-
ented. Blood collection was accurately standard-
ized, including the use of needles and vacuum 
tubes of the same lot.
Processing of diagnostic blood specimens
All the sample tubes were left in upright position 
for 45 min at room temperature (20 ºC) to allow 
complete blood clotting before centrifugation (14). 
After centrifugation at 1500 x g for 10 min at room 
temperature (according to the instructions of the 
manufacturers), serum was separated, stored in al-
iquots and kept frozen at -70 ºC until measure-
ment. All samples did not show any sign of haemo-
lysis by visual inspection. No specimen was dis-
carded due to unsatisfactory attempts, diffi  culty in 
locating venous access, missing veins, manifest 
haemolysis or lipaemia.
Laboratory testing
All serum aliquots were thawed at the same time. 
The routine clinical biochemistry tests were per-
formed in duplicate immediately after thawing on 
the same instrument cobas® 6000 <c501> module 
(Roche Diagnostics GmbH, Penzberg, Germany), 
according to the manufacturer’s specifi cations and 
using proprietary reagents. The panel of tests in-
cluded the following: glucose (GLU), total choles-
terol (COL), high density lipoprotein-cholesterol 
(HDL), triglycerides (TG), total protein (TP), albumin 
(ALB), blood urea nitrogen (UREA), creatinine (CRE), 
uric acid (AU), alkaline phosphatase (ALP), amylase 
(AMYL), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), gamma-glutamyltransfe-
ra se (GGT), lactate dehydrogenase (LDH), creatine 
kinase (CK), total bilirubin (BT), direct bilirubin (BD), 
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phosphate (P), calcium (CA), magnesium (MG), iron 
(FE), sodium (NA) and potassium (K). The instru-
ment was calibrated against appropriate proprie-
tary reference standard material and verifi ed with 
the use of proprietary quality controls. Our evalua-
tion of the within-run precision by internal quality 
control on cobas® 6000 <c501> module showed 
low coeffi  cients of variation (Table 1).
Tests DesirableBias (%) CVa
Mean % diff erence (P value)
Tube I vs. Tube II vs. Tube III vs. Tube IV vs.
Tube II Tube III Tube IV Tube V Tube III Tube IV Tube V Tube IV Tube V Tube V































































































* Non-normal distribution; P value represents the signifi cance by Wilcoxon ranked-pairs test.
**Normal distribution; P value represents the signifi cance by paired Student’s t-test.
The bold P values are statistically signifi cant (P < 0.005) and bold mean % diff erences represent clinically signifi cant variations, when compared 
with desirable bias (15).
Tube I: VACUETTE® 4.0 mL (lot C080818, Greiner bio-one, Kremsmünster, Austria); Tube II: LABOR IMPORT® 6.0 mL (lot C38005-6, Guangzhou 
Improve Medical Instruments Co. Ltda, Zhejiang, China); Tube III: S-Monovette® 4.9 mL (lot 8092506, Sarstedt, Nümbrecht, Germany); Tube IV: SST® 
4.0 mL (lot 8308434, Becton, Dickinson and Company, Franklin Lakes, NJ, USA); Tube V: SST II Advance® 5.0 mL (lot 8225174, Becton, Dickinson and 
Company, Franklin Lakes, NJ, USA).
CVa (%): Analytical coeffi  cient (within-run precision), by internal quality control on cobas® 6000 <c501> module.
CRE - creatinine; AMYL - amylase; P - phosphate; MG - magnesium; ALT - alanine aminotransferase.
TABLE 1. Variability in routine clinical biochemistry testing from fi ve diff erent brands of serum vacuum tubes with clot activator and 
gel separator.
Statistical analysis
The signifi cance of the diff erences between sam-
ples was assessed by repeated measures using RM 
ANOVA and paired Student’s t-test after checking 
for normality (with D’Agostino-Pearson’s omnibus 
test). As non-normal distribution was found for 
GLU, CRE, AU, ALT, GGT, CK, BT, FE and NA results 
were assessed by Friedman test and Wilcoxon 
ranked-pairs test using licensed statistical software 
(GraphPad Prism® version 5.01, La Jolla, CA, USA). 
Based on screening fi ve diff erent vacuum tubes in 
parallel, a P value < 0.005 was considered statisti-
cally signifi cant according to Bonferroni correction 
for multiple comparisons. Finally, the biases from 
Tube I, Tube II, Tube III, Tube IV and Tube V were 
compared with the current desirable quality speci-
fi cations for bias (B), derived from biological varia-
tion according to the formula B < 0.25 (CVw2 + 
CVg2)1/2 where CVw and CVg are within- and be-
tween-subject CVs (15).
Results
The main results of this study are shown in tables 1 
and 2. Basically, signifi cantly diff erences could be 
recorded for the following: CRE when comparing 
Tube I vs. Tube IV, Tube II vs. Tube IV and Tube III vs. 
Tube IV; AMYL when comparing Tube I vs. Tube II, 
Tube I vs. Tube III, Tube I vs. Tube IV, Tube I vs. Tube 
V, Tube II vs. Tube III, Tube II vs. Tube IV, Tube II vs. 
Tube V, Tube III vs. Tube IV, Tube III vs. Tube V and 
Tube IV vs. Tube V; P when comparing Tube II vs. 
Tube III, Tube II vs. Tube IV and Tube II vs. Tube V; 
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MG when comparing Tube I vs. Tube II, Tube I vs. 
Tube III, Tube I vs. Tube IV and Tube I vs. Tube V. No 
signifi cant diff erences (P > 0.005) were observed 
for: GLU, COL, HDL, TG, TP, ALB, UREA, AU, ALP, AST, 
ALT, GGT, LDH, CK, BT, BD, CA, FE, NA and K. Clini-
cally signifi cant variations as compared with the 
current desirable quality specifi cations (15) were 
found for: CRE when comparing Tube I vs. Tube III 
(without statistical signifi cance, P = 0.038), Tube II 
vs. Tube III (without statistical signifi cance, P = 
0.019), and Tube III vs. Tube IV and Tube III vs. Tube 
V (without statistical signifi cance, P = 0.013); AMYL 
when comparing Tube I vs. Tube III, Tube II vs. Tube 
III, Tube II vs. Tube IV, and Tube II vs. Tube V; ALT 
only when comparing Tube III vs. Tube IV (without 
statistical signifi cance, P = 0.043); MG when com-
paring Tube I vs. Tube II, Tube I vs. Tube III, Tube I 
vs. Tube IV and Tube I vs. Tube V.
Discussion
The validation process is essential in accredited 
clinical laboratories (8,16). Recently article pub-
lished by Stankovic et al. (7) showed that IVD com-
panies that are concerned about total quality in 
laboratory diagnostics have dedicated resources 
to assure total system performance. These individ-
uals collaborate with colleagues from instrument/
assay/tube companies to address particular cus-
tomer complaints and fi nd root cause and ways to 
mitigate it (7). In opposite way Bowen et al. showed 
that components from blood collection tube e.g. 
surfactants, stopper, stopper lubricant, separator 
gel and clot activator interact with blood aff ecting 
laboratory tests (17). Our results showed that both 
Stankovic et al. and Bowen et al. are partially cor-
rect. Basically, our validation will permit the labo-
ratory or hospital managers to select the brand’s 
vacuum tubes validated according him/her techni-
cal or economical reasons, in order to perform the 
following laboratory tests: GLU, COL, TG, TP, ALB, 
UREA, AU, ALP, AST, CK, BT, BD, CA, FE, NA and K. 
On the contrary special attention will be required 
in the following situations: a) if the laboratory per-
forms CRE determination and the quality labora-
tory manager intends to change the serum Tube 
IV to Tube- I, II or III; b) if the laboratory performs 
AMYL determination and the quality laboratory 
manager intends to change any of the tested 
brands of serum vacuum tubes; c) if the laboratory 
performs P determination and the quality labora-
tory manager intends to change the serum Tube II 
to Tube- III, IV or V; and d) if the laboratory already 
performs MG determination and the quality labo-
ratory manager intends to change the serum Tube 
I to Tube- II, III, IV or V (Table 1). When looking at 
the above CRE, AMYL, P and MG results (Table 2) 
one might regard them as clinically irrelevant, 
though such a conclusion is far from correct in re-
spect of the current quality specifi cations for bias, 
derived from biological variation (15). Obviously 
the quality specifi cations derived from biological 
variation (15) are considered both very important 
and useful in the daily practice by the quality man-
agers of the medical laboratories (18-21). Even in 
this case caring physicians unaware of the real pa-
tient situation might abstain from appropriate 
treatments as a consequence of change in serum 
vacuum tubes brands. The National Kidney Foun-
dation published the Kidney Disease Outcomes 
Quality Initiative (K/DOQI) Clinical Practice Guide-
lines for chronic kidney disease years ago (22). 
These guidelines recommend the use of estimated 
glomerular filtration rate (eGFR) equations to esti-
mate a patient’s renal function. At the present time 
several articles have been published about, evi-
dencing the impact of these guidelines in clinical 
practices daily (23-25). When considering that ac-
curate serum creatinine determination is neces-
sary for deriving the above eGRF equations, chang-
es of serum vacuum tubes principally from Tube III 
to Tube IV (with clinically signifi cant diff erence) can 
induce diagnostic errors regarding patient real 
conditions. Acute pancreatitis is an acute infl am-
matory condition of the pancreas, which might ex-
tend to local and distant extra pancreatic tissues. 
Diagnosis of acute pancreatitis is substantially 
based on a combination of clinical signs and symp-
toms, imaging techniques and laboratory investi-
gations (26). A host of serum enzymes such as 
amylase, lipase, trypsinogen, elastase, phospholi-
pase A2, ribonuclease, etc are available to diagnose 
acute pancreatitis and/or to assess the severity, but 
elevated amylase levels continue to be the “gold 
standard” among the serum markers (27). Our re-
sults show that the changes in serum vacuum 
Biochemia Medica 2012;22(2):180–6
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Test Tube I Tube II Tube III Tube IV Tube V P value
GLU (mmol/L)* 4.63 (4.45 - 4.76) 4.61 (4.41 - 4.76) 4.61 (4.43 - 4.72) 4.61 (4.40 - 4.76) 4.58 (4.44 - 4.74) 0.178
COL (mmol/L)** 4.64 ± 0.20 4.66 ± 0.20 4.61 ± 0.20 4.64 ± 0.20 4.66 ± 0.20 0.078
HDL (mmol/L)** 1.37 ± 0.08 1.37 ± 0.09 1.35 ± 0.08 1.35 ± 0.09 1.37 ± 0.09 0.041
TG (mmol/L)** 1.39 ± 0.16 1.38 ± 0.16 1.39 ± 0.16 1.39 ± 0.15 1.39 ± 0.15 0.286
TP (g/L)** 73.0 ± 1.0 73.0 ± 1.0 73.0 ± 1.0 73.0 ± 1.0 73.0 ± 1.0 0.432
ALB (g/L)** 42.0 ± 1.0 42.0 ± 1.0 42.0 ± 1.0 42.0 ± 1.0 42.0 ± 1.0 0.155
UREA (mmol/L)** 11.0 ± 0.8 10.9 ± 0.7 10.9 ± 0.7 10.9 ± 0.7 10.9 ± 0.7 0.450
CRE (µmol/L)* 67.2 (57.5 - 76.0) 67.2 (56.6 - 76.0) 62.8 (53.9 - 76.0) 69.0 (60.1 - 78.7) 68.1 (60.1 - 76.9) < 0.001
AU (µmol/L)* 273.6 (220.1 - 315.2) 273.6 (220.1 - 315.2) 4.5 (220.1 - 315.2) 273.6 (220.1 - 315.2) 273.6 (220.1 - 321.2) 0.736
ALP (U/L)** 70.0 ± 3.8 69.8 ± 3.6 70.4 ± 3.8 70.6 ± 3.8 70.1 ± 3.8 0.322
AMYL (U/L)** 66.6 ± 5.6 71.0 ± 5.9 61.4 ± 5.2 65.2 ± 5.4 63.2 ± 5.4 < 0.001
AST (U/L)** 23.2 ± 1.2 23.3 ± 1.3 23.6 ± 1.3 23.7 ± 1.3 23.6 ± 1.3 0.260
ALT (U/L)* 24.5 (17.2 - 35.0) 23.5 (18.5 - 34.0) 22.0 (17.5 - 36.5) 25.0 (16.8 - 32.8) 23.5 (16.8 - 35.5) 0.026
GGT (U/L)* 23.0 (17.0 - 35.0) 22.5 (16.2 - 34.0) 23.0 (17.0 - 34.2) 24.0 (16.2 - 34.0) 23.0 (17.0 - 34.2) 0.003
LDH (U/L)** 407 ± 12.4 404 ± 13.8 416 ± 12.2 412 ± 11.4 414 ± 11.4 0.039
CK (U/L)* 71 (50 - 142) 71 (50 - 140) 70 (53 - 142) 70 (53 - 144) 72 (54 - 148) 0.051
BT (µmol/L)* 8.55 (6.33 - 10.09) 8.21 (6.33 - 9.92) 8.55 (5.98 - 9.40) 8.38 (6.50 - 9.58) 8.21 (5.64 - 9.58) 0.216
BD (µmol/L)** 2.22 ± 0.34 2.39 ± 0.17 2.05 ± 0.34 2.22 ± 0.34 2.05 ± 0.34 0.417
P (mmol/L)** 1.24 ± 0.04 1.23 ± 0.04 1.24 ± 0.04 1.25 ± 0.03 1.25 ± 0.04 0.044
CA (mmol/L)** 2.36 ± 0.02 2.34 ± 0.02 2.34 ± 0.02 2.34 ± 0.02 2.34 ± 0.02 0.119
MG (mmol/L)** 0.82 ± 0.02 0.78 ± 0.02 0.78 ± 0.02 0.78 ± 0.02 0.78 ± 0.02 < 0.001
FE (µmol/L)* 18.0 (15.5 - 19.9) 18.0 (15.2 - 19.3) 18.0 (15.5 - 20.0) 18.3 (15.4 - 19.8) 18.0 (15.3 - 19.6) 0.293
NA (mmol/L)* 138.0 (138.0 - 139.0) 139.0 (138.0 - 139.0) 139.0 (138.0 - 139.8) 139.0 (138.0 - 139.0) 139.0 (138.0 - 139.8) 0.265
K (mmol/L)** 4.30 ± 0.06 4.24 ± 0.06 4.24 ± 0.05 4.27 ± 0.06 4.27 ± 0.05 0.095
*Non-normal distribution; the values are presented as median (interquartile range); P value represents the signifi cance by Friedman test
**Normal distribution; the values are presented as mean ± standard deviation; P value represents the signifi cance by RM ANOVA.
The bold P values are statistically signifi cant (P < 0.005). Tube I: VACUETTE® 4.0 mL (lot C080818, Greiner bio-one, Kremsmünster, Austria); Tube 
II: LABOR IMPORT® 6.0 mL (lot C38005-6, Guangzhou Improve Medical Instruments Co. Ltda, Zhejiang, China); Tube III: S-Monovette® 4.9 mL (lot 
8092506, Sarstedt, Nümbrecht, Germany); Tube IV: SST® 4.0 mL (lot 8308434, Becton, Dickinson and Company, Franklin Lakes, NJ, USA); Tube V: SST 
II Advance® 5.0 mL (lot 8225174, Becton, Dickinson and Company, Franklin Lakes, NJ, USA).
GLU - glucose; COL - total cholesterol; HDL - high density lipoprotein-cholesterol; TG - triglycerides; TP - total protein; ALB - albumin; UREA - 
blood urea nitrogen; CRE - creatinine; AU - uric acid; ALP - alkaline phosphatase; AMYL - amylase; AST - aspartate aminotransferase; ALT - alanine 
aminotransferase; GGT - gamma-glutamyltransferase; LDH - lactate dehydrogenase; CK - creatine kinase; BT - total bilirubin; BD - direct bilirubin; P 
- phosphate; CA - calcium; MG - magnesium; FE - iron; NA - sodium; K - potassium.
TABLE 2. Comprehensive results of routine clinical biochemistry testing from fi ve diff erent brands of serum vacuum tubes with clot 
activator and gel separator.
tubes brands principally from Tube II to Tube- III or 
V can manifest clinically signifi cant impact in med-
ical decisions based on laboratory diagnosis. As for 
phosphate, the vacuum tubes change from Tube II 
to Tube- III, IV or V can signifi cantly infl uence phos-
phates levels; in this respect we must consider 
that: a) Ferrari et al. (28) showed that serum phos-
phate is an important determinant for correcting 
serum calcium in end-stage kidney disease, b) this 
retains even if the target concentrations for phos-
phorus and calcium × phosphorus product are 
sometimes close to the normal range even in pa-
tients with end-stage kidney disease (28), c) a rela-
tionship between serum phosphate and cardio-
vascular risk factors was demonstrated by Lippi et 
al. (29). The fourth most abundant cation in the 
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human body, magnesium is, like potassium, pre-
dominantly intracellular. It is critically involved in 
energy metabolism, enzyme functions and partici-
pates in the regulation of PTH synthesis, release, 
and action (30). Low magnesium levels have been 
associated with impairment of myocardial contrac-
tility, intradialytic hemodynamic instability, and 
hypotension. In addition, low MG has been also 
linked to carotid intima-media thickness, a marker 
of atherosclerotic vascular disease and a predictor 
of vascular events (31). Magnesium sulphate is also 
acknowledged as the preferred anticonvulsant for 
eclamptic women, since it reduces the risk ratio of 
recurrence of seizures, probably reduces the risk of 
maternal death, and improves outcome for the 
children (32). Even for MG, inappropriately high 
values due to changes in vacuum tubes brands 
(from Tube I to Tube- II, III, IV or V) might induce 
diagnostic errors regarding patient real conditions. 
The 5 kinds of serum vacuum tubes evaluated 
were validated for 83.3% of the tests but obviously 
16.7% of the routine clinical chemistry testing 
needs more attention when the lab intends to 
change the serum vacuum tubes brands. In the 
same way Lima-Oliveira et al. have shown recently 
that diff erent manufacturing source of syringes is 
a new source of extra analytical variability in blood 
gas analyses (33). Similarly, as the concentration of 
clot activator additives as well as gel composition 
in the serum tubes are patented, the implicit “in-
dustrial secret” does not aid to clarify the causes of 
the bias observed in our study though it is strong-
ly hypothesized, basing on Bowen et al. (17) argu-
ments. Future investigations should be planned to 
better understand the nature of this intriguing ob-
servations; in the meantime we suggest that every 
laboratory management should both standardize 
the procedures and frequently evaluate the quali-
ty of IVD devices.
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Upravljanje kvalitetom prijeanalitičke faze: validacija vakumskih serumskih 
epruveta kod rutinskih biokemijskih pretraga
Sažetak
Uvod: Proces validacije ključan je u akreditiranim kliničkim laboratorijima. Cilj ovog istraživanja bio je validirati pet vrsta vakumskih serumskih 
epruveta koje se koriste pri rutinskim biokemijskim pretragama u laboratoriju.
Materijali i metode: Iskusni laboratorijski tehničar sakupio je uzorke krvi od 100 dobrovoljaca u pet različitih vakumskih serumskih epruveta 
(epruveta I: VACUETTE®, epruveta II: LABOR IMPORT®, epruveta III: S-Monovette®, epruveta IV: SST® i epruveta V: SST II®). U uzorcima su provede-
ne rutinske biokemijske pretrage na analizatoru cobas® 6000 modul c501. Statistička značajnost razlika između rezultata svakog uzorka procije-
njena je Studentovim t-testom nakon provjere normalnosti raspodjele. Razina statističke značajnosti postavljena je na P < 0,005. Naposljetku su 
sustavne pogreške dobivene rezultatima iz epruvete I, epruvete II, epruvete III, epruvete IV i epruvete V uspoređene s preporučenim vrijednosti-
ma odstupanja (engl. desirable quality specifi cations for bias, B) koja su izvedena iz biološke varijacije.
Rezultati i zaključak: Naša će validacija omogućiti voditeljima laboratorija ili bolnice odabrati vakumske epruvete određenog proizvođača 
validirane prema vlastitim tehničkim ili ekonomskim zahtjevima, za sljedeće pretrage: glukozu, ukupni kolesterol, HDL-kolesterol, trigliceride, 
ukupne proteine, albumin, ureju, mokraćnu kiselinu, alkalnu fosfatazu, aspartat-aminotransferazu, gama-glutamiltransferazu, laktat-dehidro-
genazu, kreatinin-kinazu, ukupni bilirubin, direktni bilirubin, kalcij, željezo, natrij i kalij. Posebna se pažnja treba obratiti ukoliko laboratorij već 
vrši pretrage za određivanje koncentracije kreatinina, fosfora i magnezija te aktivnosti amilaze, ukoliko voditelj upravljanja kvalitetom labo-
ratorija želi promijeniti serumske epruvete. Predlažemo da voditelj laboratorija standardizira postupke i redovito procjenjuje kvalitetu in vitro 
dijagnostičkih uređaja.
Ključne riječi: prijeanalitička varijabilnost; uzorkovanje; uzorci seruma; vakumske epruvete; proces validacije
